Cargando…
Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR
SHP2 mediates RAS activation downstream of multiple receptor tyrosine kinases (RTKs) and cancer cell lines dependent on RTKs are in general dependent on SHP2. Profiling of the allosteric SHP2 inhibitor SHP099 across cancer cell lines harboring various RTK dependencies reveals that FGFR-dependent cel...
Autores principales: | Lu, Hengyu, Liu, Chen, Huynh, Hung, Le, Thi Bich Uyen, LaMarche, Matthew J., Mohseni, Morvarid, Engelman, Jeffrey A., Hammerman, Peter S., Caponigro, Giordano, Hao, Huai-Xiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980623/ https://www.ncbi.nlm.nih.gov/pubmed/32076487 http://dx.doi.org/10.18632/oncotarget.27435 |
Ejemplares similares
-
Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma
por: Prawira, Aldo, et al.
Publicado: (2020) -
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
por: LaRochelle, Jonathan R., et al.
Publicado: (2018) -
Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor
por: Prawira, Aldo, et al.
Publicado: (2021) -
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023) -
Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)